Epigral Limited
NSE: EPIGRALMarket Closed • NSE
Day range
52 week range
Epigral Limited closed at INR995.80 (+2.2%) on volume 0.58x its 20-day average, trading 42.44% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +23.5% QoQ
2026-06-01
DIVIDEND Announced
Dividend - Rs 5 Per Share
2025-06-20
DIVIDEND Announced
Dividend - Rs 3.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 15.5%
Low Debt Profile: Debt-to-Equity is comfortable at 0.26x
High Cash Flow Conversion: CFO/PAT averaged 1.31x over last 3 years
Attractive Valuation: P/E of 15.9x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Chemicals.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 01 Jun 2026 | Dividend | ₹5.00 / share | — | 01 Jun 2026 |
| 21 Jun 2025 | Dividend | ₹3.50 / share | — | 20 Jun 2025 |
| 07 Feb 2025 | Dividend | ₹2.50 / share | — | 07 Feb 2025 |
| 02 Jul 2024 | Dividend | ₹5.00 / share | — | 02 Jul 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Jun 2023 |
| 20 Jun 2023 | Dividend | ₹2.50 / share | — | 20 Jun 2023 |
| 01 Feb 2023 | Dividend | ₹2.50 / share | — | 01 Feb 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 17 Jun 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 15 Sept 2021 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 UltraTech Cement LimitedULTRACEMCO Open analysis | ₹3.21L | 37.59 | 2.21% | ₹25,799.47 | ₹2,982.76 | +11.86% | +20.17% |
 JSW Steel LimitedJSWSTEEL Open analysis | ₹2.97L | 12.05 | 0.59% | ₹47,364.00 | ₹4,651.00 | +11.55% | +112.96% |
 Hindustan Zinc LimitedHINDZINC Open analysis | ₹2.28L | 13.37 | 2.07% | ₹13,687.00 | ₹5,425.00 | +77.22% | +146.14% |
 Asian Paints LimitedASIANPAINT Open analysis | ₹2.24L | 46.94 | 1.17% | ₹10,541.94 | ₹1,539.25 | +17.94% | +39.96% |
 Tata Steel LimitedTATASTEEL Open analysis | ₹2.19L | 19.83 | 2.27% | ₹60,794.00 | ₹2,385.00 | +14.32% | +18.83% |
 Hindalco Industries LimitedHINDALCO Open analysis | ₹2.02L | 12.32 | 0.56% | ₹84,825.00 | ₹7,013.00 | +32.06% | +75.15% |
 Grasim Industries LimitedGRASIM Open analysis | ₹1.98L | 34.82 | 0.35% | ₹11,794.71 | ₹246.65 | -70.60% | -82.61% |
 Solar Industries India LimitedSOLARINDS Open analysis | ₹1.81L | 90.93 | 0.06% | ₹3,668.00 | ₹666.00 | +70.29% | +88.67% |
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals.[1]
IndiaBasic Materials
Is Epigral Limited Shariah compliant?
Epigral Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (13.31%) complies with AAOIFI threshold (≤ 33%).
What is Epigral Limited's current valuation relative to peers?
Epigral Limited trades at a P/E of 15.9x compared to the sector median of 21.9x, and a Price-to-Book of 1.9x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.26x and a Net Debt to EBITDA ratio of 1.01x. Interest coverage is 7.9x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 0.1% while net profit growth averaged -1.5%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.